- Blood Sugar
- Clinical Studies
- Complementary Medicine
- Diabetes and Men
- Erectile Dysfunction
- Food and Nutrition
- Insulin Pumps
- Meters and Test Strips
- Product Recalls
- Type 1
- Type 2
- Weight Loss Surgery
August 31, 2015 (Newswise) — Rutgers Cancer Institute of New Jersey population science researcher XiangLin Tan, MD, PhD, has been awarded an $852,705 Career Development Award (K07CA190541) from the National Cancer Institute to explore the use of aspirin and a diabetes drug for prostate cancer prevention and control, especially in obese men.
Excluding skin cancer, prostate cancer is the most frequently diagnosed cancer in American men and the second leading cause of male cancer-relat
August 31, 2015 (MedicalXPress) — Women aged 45 years and under with diabetes have a six-fold risk of heart attack, according to research presented at ESC Congress today. The study in more than 7 000 women also found that young women who had a heart attack (myocardial infarction, MI) were more likely to be smokers than older women with MI.
"Cardiovascular diseases (CVDs) affect mainly the elderly, but for many years an increase in incidence has been observed in young people
August 31, 2015 (Reuters) — Google Inc and French drugmaker Sanofi SA said they will partner to develop tools to improve the management and treatment of diabetes.
Sanofi will work with Google's life sciences team to collect, analyze and understand information impacting diabetes, which is expected to affect 592 million by 2035, according to the International Diabetes Federation.
Sanofi's diabetes product line raked in sales of 1.9 billion euros ($2.13 bill
August 31, 2015 (Pharma Times) - US regulators have issued a green light for Boehringer Ingelheim and Eli Lilly's new combination diabetes therapy Synjardy.
The US Food and Drug Administration says the drug - a fixed-dose combination of empagliflozin and metformin - can be used as an ajunct to diet and exercise to control blood sugar levels in patients with type II diabetes.
The pill's two components have very different modes of action: empagliflozin is
August 31, 2015 (HealthDay News) -- Use of a class of widely prescribed medications for type 2 diabetes is tied to severe joint pain in some patients, the U.S. Food and Drug Administration warned on Friday.
The drugs -- sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta) and alogliptin (Nesina) -- come from a newer class of medications called DPP-4 inhibitors.
The drugs can be t